Photo from Yüksel Ürün/X
Aug 4, 2024, 05:15
Yüksel Ürün: U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy
Yüksel Ürün shared on X:
“U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy.
- Approved with carboplatin/paclitaxel, then single-agent dostarlimab-gxly, for primary advanced/recurrent endometrial cancer.
- Median OS 44.6 months vs. 28.2 months.
- Common adverse reactions: anemia, fatigue, neuropathy.”
Source: Yüksel Ürün/X
Other posts featuring Yüksel Ürün on OncoDaily.
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14
Nov 14, 2024, 16:29